by jlohrconsulting | Sep 3, 2025 | Uncategorized
Can J Psychiatry. 2025 Sep 3:7067437251374564. doi: 10.1177/07067437251374564. Online ahead of print. ABSTRACT Co-occurring alcohol use disorder (AUD) and major depressive disorder (MDD) are common and complex conditions that significantly impact patient outcomes. The...
by jlohrconsulting | Sep 3, 2025 | Uncategorized
J Clin Psychiatry. 2025 Sep 3;86(3):25m15868. doi: 10.4088/JCP.25m15868. ABSTRACT Objective: To assess proof-of-concept (PoC) for efficacy, tolerability, and safety of TRPC4/5 inhibitor BI 1358894 vs placebo in patients with major depressive disorder (MDD) with...
by jlohrconsulting | Sep 3, 2025 | Uncategorized
J Clin Psychiatry. 2025 Sep 3;86(4):25m15970. doi: 10.4088/JCP.25m15970. ABSTRACT Background: On October 7, 2023, Israel experienced a large-scale terrorist attack followed by a prolonged war, exposing civilians and military personnel to acute and sustained trauma....
by jlohrconsulting | Sep 3, 2025 | Uncategorized
J Clin Psychiatry. 2025 Sep 3;86(4):25m15781. doi: 10.4088/JCP.25m15781. ABSTRACT Objective: Electroconvulsive therapy (ECT) has potent antidepressant effects yet can lead to neurocognitive side effects. Ketamine is a rapid-acting antidepressant, which may be an...
by jlohrconsulting | Sep 3, 2025 | Uncategorized
J Paediatr Child Health. 2025 Sep 3. doi: 10.1111/jpc.70188. Online ahead of print. NO ABSTRACT PMID:40899605 | DOI:10.1111/jpc.70188
by jlohrconsulting | Sep 3, 2025 | Uncategorized
Int J Soc Psychiatry. 2025 Sep 3:207640251368256. doi: 10.1177/00207640251368256. Online ahead of print. NO ABSTRACT PMID:40899969 | DOI:10.1177/00207640251368256
Recent Comments